Literature DB >> 29313654

Lung Cancer: Clinical Presentation and Diagnosis.

Kelly M Latimer1.   

Abstract

In the absence of screening, most patients with lung cancer are not diagnosed until later stages, when the prognosis is poor. The most common symptoms are cough and dyspnea, but the most specific symptom is hemoptysis. Digital clubbing, though rare, is highly predictive of lung cancer. Symptoms can be caused by the local tumor, intrathoracic spread, distant metastases, or paraneoplastic syndromes. Clinicians should suspect lung cancer in symptomatic patients with risk factors. The initial study should be chest x-ray, but if results are negative and suspicion remains, the clinician should obtain a computed tomography scan with contrast. The diagnostic evaluation for suspected lung cancer includes tissue diagnosis, staging, and determination of functional capacity, which are completed simultaneously. Tissue samples should be obtained using the least invasive method possible. Management is based on the individual tumor histology, molecular testing results, staging, and performance status. The management plan is determined by a multidisciplinary team consisting of a pulmonology subspecialist, medical oncology subspecialist, radiation oncology subspecialist, and thoracic surgeon. The family physician should remain involved with the patient to ensure that patient priorities are supported and, if necessary, to arrange for end-of-life care. Written permission from the American Academy of Family Physicians is required for reproduction of this material in whole or in part in any form or medium.

Entities:  

Mesh:

Year:  2018        PMID: 29313654

Source DB:  PubMed          Journal:  FP Essent        ISSN: 2159-3000


  9 in total

1.  Characteristics and Prognostic Analysis of 55 Patients With Pulmonary Sarcomatoid Carcinoma.

Authors:  Jiachun Sun; Zhiyi Jiang; Tanyou Shan; Ruina Yang; Dejiu Kong; Junshuai Rui; Xinyang Li; Guoqiang Kong; Baoping Chang
Journal:  Front Oncol       Date:  2022-05-03       Impact factor: 5.738

2.  Support Vector Machine for Lung Adenocarcinoma Staging Through Variant Pathways.

Authors:  Feng Di; Chunxiao He; Guimei Pu; Chunyi Zhang
Journal:  G3 (Bethesda)       Date:  2020-07-07       Impact factor: 3.154

3.  MicroRNA‑208a directly targets Src kinase signaling inhibitor 1 to facilitate cell proliferation and invasion in non‑small cell lung cancer.

Authors:  Li Liu; Wuzhang Wang; Song Gao; Xiuwen Wang
Journal:  Mol Med Rep       Date:  2019-07-31       Impact factor: 2.952

4.  Exploring potential biomarkers for lung adenocarcinoma using LC-MS/MS metabolomics.

Authors:  Liang Mo; Bing Wei; Renji Liang; Zhi Yang; Shouzhi Xie; Shengrong Wu; Yong You
Journal:  J Int Med Res       Date:  2020-04       Impact factor: 1.671

Review 5.  The barriers to initiating lung cancer care in low-and middle-income countries.

Authors:  Buhle Lubuzo; Themba Ginindza; Khumbulani Hlongwana
Journal:  Pan Afr Med J       Date:  2020-02-12

Review 6.  The Role of Mitochondrial miRNAs in the Development of Radon-Induced Lung Cancer.

Authors:  Assiya Kussainova; Olga Bulgakova; Akmaral Aripova; Zumama Khalid; Rakhmetkazhi Bersimbaev; Alberto Izzotti
Journal:  Biomedicines       Date:  2022-02-11

7.  SOX2 regulates paclitaxel resistance of A549 non‑small cell lung cancer cells via promoting transcription of ClC‑3.

Authors:  Youwei Huang; Xiangyu Wang; Rendong Hu; Guopeng Pan; Xi Lin
Journal:  Oncol Rep       Date:  2022-09-07       Impact factor: 4.136

8.  FGL2 is positively correlated with enhanced antitumor responses mediated by T cells in lung adenocarcinoma.

Authors:  Kai Yuan; Yanyan Feng; Hesong Wang; Lu Zhao; Wei Wang; Ting Wang; Yuyin Feng; Guangrui Huang; Anlong Xu
Journal:  PeerJ       Date:  2020-03-13       Impact factor: 2.984

9.  High expression of PIMREG predicts poor survival outcomes and is correlated with immune infiltrates in lung adenocarcinoma.

Authors:  Feng Jiang; Min Liang; Xiaolu Huang; Wenjing Shi; Yumin Wang
Journal:  PeerJ       Date:  2021-07-06       Impact factor: 2.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.